- Home
- NXPI vs MRNA Comparison
NXPI vs MRNA Comparison
Compare NXPI & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXPI | MRNA |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.0B | 61.6B |
| IPO Year | 2007 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NXPI | MRNA |
|---|---|---|
| Price | $221.15 | $223.89 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 30 | 23 |
| Target Price | ★ $306.66 | $122.67 |
| AVG Volume (30 Days) | 2.8M | ★ 13.9M |
| Earning Date | 10-27-2026 | 11-06-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 4.43 | N/A |
| Revenue | $12,269,000,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $16.17 | $8.09 |
| Revenue Next Year | $11.61 | $16.07 |
| P/E Ratio | $51.09 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $183.00 | $22.28 |
| 52 Week High | $339.95 | $227.46 |
Technical Indicators
Market Signals| Indicator | NXPI | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 38.71 | 70.65 |
| Support Level | $217.55 | $45.39 |
| Resistance Level | $243.31 | N/A |
| Average True Range (ATR) | 6.17 | 13.87 |
| MACD | -1.67 | 0.53 |
| Stochastic Oscillator | 9.34 | 92.06 |
Price Performance
Historical ComparisonAbout NXPI NXP Semiconductors N.V.
NXP Semiconductors is a leading supplier of high-performance mixed-signal products. The firm acquired Freescale Semiconductor in 2015 and now has significant market share in the automotive market, where it supplies microcontrollers and analog chips into automotive clusters, powertrains, infotainment systems, and radars. NXP Semiconductors also serves industrial and Internet of Things, mobile, and communications infrastructure.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.